(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.It should be noted that the reported patient effect of hypersensitivity is listed in the xience sierra everolimus eluting coronary stent systems instructions for use (ifu) as a known patient effect(s) of coronary stenting procedures.A conclusive cause for the reported patient effect(s), and the relationship to the product, if any, cannot be determined.However, the treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that on (b)(6) 2018, a xience sierra stent was implanted without reported issues.On (b)(6) 2018, the patient was re-admitted due to an allergic reaction (allergic urticarial) due to an unspecified drug.It is unknown if this is related to the device.No additional information was provided regarding this issue.
|